These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 2770115)

  • 1. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease.
    Felsenfeld AJ; Rodriguez M; Coleman M; Ross D; Llach F
    Kidney Int; 1989 Jun; 35(6):1371-8. PubMed ID: 2770115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteomalacia and bone disease arising from aluminum.
    Coburn JW; Norris KC; Nebeker HG
    Semin Nephrol; 1986 Mar; 6(1):68-89. PubMed ID: 3110896
    [No Abstract]   [Full Text] [Related]  

  • 3. Aluminum-related osteomalacia: clinical and histological improvement following treatment with desferrioxamine (DFO).
    Rapoport J; Chaimovitz C; Abulfil A; Mostovlavsky M; Gazit D; Bab I
    Isr J Med Sci; 1987 Dec; 23(12):1242-6. PubMed ID: 3440748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 5. Bone histologic response to deferoxamine in aluminum-related bone disease.
    Andress DL; Nebeker HG; Ott SM; Endres DB; Alfrey AC; Slatopolsky EA; Coburn JW; Sherrard DJ
    Kidney Int; 1987 Jun; 31(6):1344-50. PubMed ID: 2441107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hysteresis of the parathyroid hormone response to hypocalcemia in hemodialysis patients with low turnover aluminum bone disease.
    Felsenfeld AJ; Ross D; Rodriguez M
    J Am Soc Nephrol; 1991 Dec; 2(6):1136-43. PubMed ID: 1777594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
    Hodsman AB; Hood SA; Brown P; Cordy PE
    J Lab Clin Med; 1985 Dec; 106(6):674-81. PubMed ID: 4067379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of dialysis osteomalacia with desferrioxamine.
    Brown DJ; Dawborn JK; Ham KN; Xipell JM
    Lancet; 1982 Aug; 2(8294):343-5. PubMed ID: 6124756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine.
    Coburn JW; Norris KC
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):12-21. PubMed ID: 3299588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aluminium-induced bone disease in uremic rats: effect of deferoxamine.
    Jablonski G; Klem KH; Danielsen CC; Mosekilde L; Gordeladze JO
    Biosci Rep; 1996 Feb; 16(1):49-63. PubMed ID: 8861540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of discontinuation of aluminum exposure on aluminum-induced osteomalacia.
    Finch JL; Bergfeld M; Martin KJ; Chan YL; Teitelbaum S; Slatopolsky E
    Kidney Int; 1986 Sep; 30(3):318-24. PubMed ID: 3784278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
    Sherrard DJ; Walker JV; Boykin JL
    Am J Kidney Dis; 1988 Aug; 12(2):126-30. PubMed ID: 3400633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients.
    Tzamaloukas AH
    Med Clin North Am; 1990 Jul; 74(4):961-74. PubMed ID: 2195265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of dialysis osteomalacia and dementia, using desferrioxamine infusions and oral 1-alpha hydroxycholecalciferol.
    Hood SA; Clark WF; Hodsman AB; Bolton CF; Cordy PE; Anderson C; Leung F
    Am J Nephrol; 1984; 4(6):369-74. PubMed ID: 6517116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of parathyroidectomy on aluminum toxicity and azotemic bone disease in the rat.
    Rodriguez M; Lorenzo V; Felsenfeld AJ; Llach F
    J Bone Miner Res; 1990 Apr; 5(4):379-86. PubMed ID: 2343777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic aluminum intoxication in patients with terminal kidney failure on programmed hemodialysis (literature review)].
    Milovanova LIu; Nikolaev AIu; Barashkov GK
    Ter Arkh; 2001; 73(6):67-9. PubMed ID: 11521528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.